Literature DB >> 32869982

Intact Protein Mass Spectrometry for Therapeutic Protein Quantitation, Pharmacokinetics, and Biotransformation in Preclinical and Clinical Studies: An Industry Perspective.

John F Kellie1, John C Tran2, Wenying Jian3, Barry Jones4, John T Mehl5, Ying Ge6, Jack Henion7, Kevin P Bateman8.   

Abstract

Recent advancements in immunocapture methods and mass spectrometer technology have enabled intact protein mass spectrometry to be applied for the characterization of antibodies and other large biotherapeutics from in-life studies. Protein molecules have not been traditionally studied by intact mass or screened for catabolites in the same manner as small molecules, but the landscape has changed. Researchers have presented methods that can be applied to the drug discovery and development stages, and others are exploring the possibilities of the new approaches. However, a wide variety of options for assay development exists without clear recommendation on best practice, and data processing workflows may have limitations depending on the vendor. In this perspective, we share experiences and recommendations for current and future application of mass spectrometry for biotherapeutic molecule monitoring from preclinical and clinical studies.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32869982     DOI: 10.1021/jasms.0c00270

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  4 in total

1.  Top-down proteomics: challenges, innovations, and applications in basic and clinical research.

Authors:  Kyle A Brown; Jake A Melby; David S Roberts; Ying Ge
Journal:  Expert Rev Proteomics       Date:  2020-12-17       Impact factor: 3.940

Review 2.  Approaches to Heterogeneity in Native Mass Spectrometry.

Authors:  Amber D Rolland; James S Prell
Journal:  Chem Rev       Date:  2021-09-01       Impact factor: 72.087

3.  The Human Proteoform Project: Defining the human proteome.

Authors:  Lloyd M Smith; Jeffrey N Agar; Julia Chamot-Rooke; Paul O Danis; Ying Ge; Joseph A Loo; Ljiljana Paša-Tolić; Yury O Tsybin; Neil L Kelleher
Journal:  Sci Adv       Date:  2021-11-12       Impact factor: 14.136

4.  Assessment of Antibody Stability in a Novel Protein-Free Serum Model.

Authors:  Joachim Schuster; Vinay Kamuju; Roman Mathaes
Journal:  Pharmaceutics       Date:  2021-05-22       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.